Professional Documents
Culture Documents
N 0241092
1
Pathophysiology of Alzheimers
Disease
Treatment of Alzheimers
Disease
No permanent cure for Alzheimers disease.
The class of drugs used in the treatment of Alzheimers Disease are
Donepezil: 2-[(1-benzyl-4piperidyl)methyl]-5,6-dimethoxy-2,3
dihydroinden-1-one
Galantamine: (4aS, 6R, 8aS)-5, 6, 9, 10, 11, 12hexahydro-3-methoxy-11-methyl-4aH-[1]
benzofuro[3a, 3, 2-ef] [2] benzapin-6-ol
Rivastigmine: (S)-N-Ethyl-N-methyl-3-[1-(dimethylamino)
ethyl]-phenyl carbamate
Minor groove
Major groove
The active site gorge has two binding sites, a catalytic site (consisting of the catalytic triad together with Trp84 &
Phe330) and a peripheral site (including Trp 279 & Tyr 121), which helps prebind the substrate and direct it toward the
active site.
Bioavailability: 100%
Half-life elimination: 70 hours; time to steady-state: 15 days
Time to peak, plasma: 3-4 hours
The X-ray structure of the Donepezil-TcAChE complex shows that Donepezil has unique orientation with active-site
gorge.
Donepezil does not, however, interact directly with either the catalytic triad or the 'oxyanion hole' but only indirectly 7
via solvent molecules
Cholinesterase inhibitors for patients with Alzheimers Disease: Systematic review of randomised clinical trials BMJ 2005;331;321-327
Cholinesterase inhibitors for patients with Alzheimers Disease: Systematic review of randomised clinical trials BMJ 2005;331;321-327
10
Cholinesterase inhibitors for patients with Alzheimers Disease: Systematic review of randomised clinical trials BMJ 2005;331;321-327
11
Cholinesterase inhibitors for patients with Alzheimers Disease: Systematic review of randomised clinical trials BMJ 2005;331;321-327
12
From the clinical trials, it is evident that Donepezil has a better effect as a
Acetylcholinesterase Inhibitor as compared to Galantamine or Rivastigmine.
However, further research is still on to determine the extent of the beneficial nature of
Donepezil as compared to Galantamine and Rivastigmine.
13
14